Lv55
1064 积分 2024-03-20 加入
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
22天前
已关闭
Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial
25天前
已完结
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
1个月前
已完结
Faculty Opinions recommendation of Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia
1个月前
已关闭
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
1个月前
已完结
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
1个月前
已完结
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
1个月前
已完结
儿童非输血依赖型地中海贫血诊治和管理专家共识（2025）
1个月前
已完结
[Guideline for the diagnosis and management of multiple myeloma-related renal impairment (2024 version)]
1个月前
已完结
皖公网安备34019202002308
